Cyclacel Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 7.42 million compared to USD 5.29 million a year ago. Basic loss per share from continuing operations was USD 9 compared to USD 8.1 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | +4.00% | +56.62% | -20.22% |
May. 02 | Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding | CI |
Apr. 30 | Top Midday Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.22% | 2.64M | |
+8.64% | 105B | |
-0.90% | 104B | |
+5.44% | 22.94B | |
-12.25% | 22.34B | |
-6.31% | 19.25B | |
-37.08% | 17.08B | |
-8.69% | 16.96B | |
+7.59% | 14.16B | |
+38.96% | 12.63B |
- Stock Market
- Equities
- CYCC Stock
- News Cyclacel Pharmaceuticals, Inc.
- Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022